Cargando…

The association between distal symmetric polyneuropathy in diabetes with all-cause mortality – a meta-analysis

BACKGROUND: Distal symmetric polyneuropathy (DSPN) is a common microvascular complication of both type 1 and 2 diabetes with substantial morbidity burden and reduced quality of life. Its association with mortality is equivocal. PURPOSE: To describe the association between DSPN and all-cause mortalit...

Descripción completa

Detalles Bibliográficos
Autores principales: Vági, Orsolya E., Svébis, Márk M., Domján, Beatrix A., Körei, Anna E., Tesfaye, Solomon, Horváth, Viktor J., Kempler, Péter, Tabák, Ádám Gy.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978416/
https://www.ncbi.nlm.nih.gov/pubmed/36875485
http://dx.doi.org/10.3389/fendo.2023.1079009
Descripción
Sumario:BACKGROUND: Distal symmetric polyneuropathy (DSPN) is a common microvascular complication of both type 1 and 2 diabetes with substantial morbidity burden and reduced quality of life. Its association with mortality is equivocal. PURPOSE: To describe the association between DSPN and all-cause mortality in people with diabetes and further stratify by the type of diabetes based on a meta-analysis of published observational studies. DATA SOURCES: We searched Medline from inception to May 2021. STUDY SELECTION: Original data were collected from case-control and cohort studies that reported on diabetes and DSPN status at baseline and all-cause mortality during follow-up. DATA EXTRACTION: was completed by diabetes specialists with clinical experience in neuropathy assessment. DATA SYNTHESIS: Data was synthesized using random-effects meta-analysis. The difference between type 1 and 2 diabetes was investigated using meta-regression. RESULTS: A total of 31 cohorts (n=155,934 participants, median 27.4% with DSPN at baseline, all-cause mortality 12.3%) were included. Diabetes patients with DSPN had an almost twofold mortality (HR: 1.96, 95%CI: 1.68-2.27, I2 = 91.7%), I(2 =) 91.7%) compared to those without DSPN that was partly explained by baseline risk factors (adjusted HR: 1.60, 95%CI: 1.37-1.87, I(2 =) 78.86%). The association was stronger in type 1 compared to type 2 diabetes (HR: 2.22, 95%CI: 1.43-3.45). Findings were robust in sensitivity analyses without significant publication bias. LIMITATIONS: Not all papers reported multiple adjusted estimates. The definition of DSPN was heterogeneous. CONCLUSIONS: DSPN is associated with an almost twofold risk of death. If this association is causal, targeted therapy for DSPN could improve life expectancy of diabetic patients.